Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 84 pages | ID: O699C46E51FFEN
Global Markets Direct

Abstracts

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 2, 3 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Gastrointestinal and Toxicology which include indications Narcolepsy, Insomnia, Obstructive Sleep Apnea, Hypersomnia, Unspecified Neurologic Disorders, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease (COPD), Delirium, Dementia, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Mild Cognitive Impairment, Neurology, Opioid Induced Side Effects, Parkinson's Disease, Reflux Esophagitis (Gastroesophageal Reflux Disease), Respiratory Depression (Hypoventilation) and Sleep Disorders.

The latest report Orexin Receptor Type 2 - Drugs In Development, 2022, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
• The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction
Global Markets Direct Report Coverage
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development
Centessa Pharmaceuticals Plc
Eisai Co Ltd
Idorsia Pharmaceutical Ltd
Inexia Ltd
Johnson & Johnson
Merck & Co Inc
NLS Pharmaceutics AG
Sumitomo Pharma Co Ltd
Synchronicity Pharma Inc
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles
ALKS-2680 - Drug Profile
Product Description
Mechanism Of Action
History of Events
danavorexton - Drug Profile
Product Description
Mechanism Of Action
History of Events
daridorexant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
DSP-0187 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lemborexant - Drug Profile
Product Description
Mechanism Of Action
History of Events
mazindol ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
OX2 agonist - Drug Profile
Product Description
Mechanism Of Action
History of Events
OX2 agonist (Oral) - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptides to Agonize Orexin 2 Receptor for Narcolepsy and Unspecified Neurologic Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
seltorexant - Drug Profile
Product Description
Mechanism Of Action
History of Events
suvorexant - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-861 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-994 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TS-142 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YZJ-1139 - Drug Profile
Product Description
Mechanism Of Action
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones
Featured News & Press Releases
Jul 21, 2022: NLS pharmaceutics announces positive opinion from European Regulators to grant Orphan Drug Designation for Mazindol ER in idiopathic hypersomnia
Jul 19, 2022: Idorsia announces World Champion Skier, Philanthropist and Entrepreneur Lindsey Vonn as patient ambassador for QUVIVIQ (daridorexant), a Once Nightly Treatment for Insomnia
Jun 03, 2022: Eisai to present latest data on lemborexant at the 36th Annual SLEEP 2022 Meeting
Jun 02, 2022: NLS Pharmaceutics announces over enrollment in its phase 2a clinical trial evaluating Quilience(R) for the treatment of narcolepsy
May 13, 2022: Idorsia U.S. announces first wave of patients prescribed QUVIVIQ (daridorexant) through partnership with pharmacy services provider
May 04, 2022: NLS Pharmaceutics achieves 90% enrollment milestone in Quilience phase 2a clinical trial for patients with narcolepsy
May 03, 2022: Europe’s first dual orexin receptor antagonist - QUVIVIQ (daridorexant) - granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder
May 02, 2022: Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia
Mar 28, 2022: NLS Pharmaceutics announces Early Access Program (EAP) allowing patients with idiopathic hypersomnia to receive treatment with Mazindol ER
Mar 16, 2022: NLS Pharmaceutics announces positive interim top-line data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
Mar 10, 2022: New data for daridorexant in patients with insomnia disorder - including long-term safety and efficacy - to be presented at World Sleep 2022
Feb 25, 2022: QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder
Feb 07, 2022: NLS Pharmaceutics to present interim top-line data for Quilience (Mazindol ER) in patients with narcolepsy at the World Sleep Congress in March 2022
Jan 20, 2022: The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
Jan 10, 2022: Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Centessa Pharmaceuticals Plc, 2022
Pipeline by Eisai Co Ltd, 2022
Pipeline by Idorsia Pharmaceutical Ltd, 2022
Pipeline by Inexia Ltd, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by NLS Pharmaceutics AG, 2022
Pipeline by Sumitomo Pharma Co Ltd, 2022
Pipeline by Synchronicity Pharma Inc, 2022
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by Yangtze River Pharmaceutical Group, 2022
Dormant Products, 2022
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022